Recent Updates — BDMD
On September 24, 2026, Baird Medical Investment Holdings Limited entered into a Securities Purchase Agreement to issue a senior convertible promissory note with a principal amount of US$4,347,826. The note carries an 8% original issue discount and a term of 12 months, with conversion priced at the lower of $0.9842 or 92% of the lowest daily VWAP over seven trading days prior to conversion. The company issued 110,070 ordinary shares as part of an additional discount mechanism based on a closing price of $0.79. The agreement includes options for the purchaser to lend an additional $3,680,000 within 180 days and up to $6 million within 360 days, subject to specific conditions. The transaction is secured by a pledge of equity interests in Baird Med LLC and a security interest in substantially all U.S.-located assets of the company and its subsidiaries. Baird Medical Investment Holdings Limited operates in the healthcare sector, focusing on medical device innovation and commercialization.
Baird Medical Investment Holdings Limited reported a net income of $13,499 for the six months ended June 30, 2026, a significant turnaround from an $11.4 million net loss in the prior year period. Revenues increased 24.6% to $9.9 million, driven by $4.8 million in new technology licensing revenue that partially offset a $3.0 million decline in microwave ablation device sales. Adjusted EBITDA turned positive at $4.0 million compared to negative $3.3 million previously. The company also announced a subsequent event financing of approximately $4 million via senior 8% convertible promissory notes issued on September 8, 2026. Baird Medical Investment Holdings Limited operates in the medical technology industry, specializing in non-invasive thyroid treatment solutions and microwave ablation devices.
Baird Medical Investment Holdings Ltd. reported preliminary unaudited financial results for the six months ended June 30, 2026, showing revenue of approximately $9.9 million, a 24.6% increase from $8.0 million in the prior year period. Gross profit rose 32.0% to $8.6 million with an improved gross margin of 87.0%, driven by geographic sales shifts and licensing revenue. Total operating expenses decreased significantly to $7.8 million from $17.0 million, primarily due to reductions in research and development and general administrative costs. The company achieved net income of approximately $14,000 compared to a net loss of $(11.4) million previously, alongside EBITDA of $1.6 million and adjusted EBITDA of $4.0 million. U.S. revenue contributed approximately 27% of the total, reflecting successful commercial expansion in key territories including Argentina, Vietnam, and Pakistan. Baird Medical is a global medical device company specializing in minimally invasive ablation technologies for solid tumors.